UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   FORM 10-QSB

 [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE
                                   ACT OF 1934

               For the quarterly period ended: September 30, 2005

                                       or

[_] TRANSITION REPORT PURSUANT TO SECTION 13 0R 15(D) OF THE SECURITIES EXCHANGE
                                   ACT OF 1934

                For the transition period from ______ to _______

                        Commission File Number: 000-51497

                            BIO-BRIDGE SCIENCE, INC.

        (Exact name of small business issuer as specified in its charter)



         Delaware                                               20-1802936
------------------------------                              -------------------
(State or Other jurisdiction of                               (IRS Employer
incorporation or organization)                              Identification No.)

   1211 West 22nd Street, Suite 615
         Oak Brook, Illinois                                     60523
(Address of principal executive offices)                       (Zip Code)


                                  630-928-0869
                                  ------------
                 (Issuer's telephone number including area code)

Check whether the issuer (1) has filed all reports required to be filed by
Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant was required to file
such reports), and (2) has been subject to such filing requirements for the past
90 days.

Yes [_] No [X]

State the number of shares outstanding of each of the issuer's classes of common
stock, as of the latest practicable date.

Common Stock Outstanding as of November 1, 2005: 32,471,537 shares

Transitional Small Business Disclosure Format: Yes [_] No [X]


<PAGE>

                             Bio-Bridge Science, Inc

                              Index to Form 10-QSB

                                                                            Page

Item 1.   Financial Statements                                                3

          Balance Sheet as of December 31, 2004 and September 30, 2005
          (unaudited) 4

          Unaudited Statements of Operations for the three and nine
          month periods ended September, 2005 and September 30, 2004          4

          Unaudited Statements of Changes in Shareholders' Equity
          for the period from February 11, 2002 (inception) through
          September 30, 2005                                                  5

          Unaudited Statements of Cash flows for the nine month periods
          ended September 30, 2005 and September 30, 2004                     6

          Notes to Unaudited Financial Statements                             7

Item 2.   Management's Discussion and Analysis or Plan of Operation          12

Item 3.   Controls and Procedures                                            16

Part II   Other Information                                                  17

Item 1.   Legal Proceedings                                                  17

Item 2.   Unregistered Sales of Equity Securities and Use of Proceeds        17

Item 3.   Defaults Upon Senior Securities                                    17

Item 4.   Submission of Matters to a Vote of Security Holders                17

Item 5.   Other Information                                                  17

Item 6.   Exhibits                                                           17

          SIGNATURES                                                         18


                                        2
<PAGE>

                         PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

                    BIO-BRIDGE SCIENCE, INC. AND SUBSIDIARIES
                          (A DEVELOPMENT STAGE COMPANY)
                      CONDENSED CONSOLIDATED BALANCE SHEETS

                                     ASSETS
                                     ------
<TABLE>
<CAPTION>
                                                                   September 30,      December 31,
                                                                       2005              2004
                                                                  --------------    --------------
                                                                   (UNAUDITED)
<S>                                                               <C>               <C>
CURRENT ASSETS

  Cash and cash equivalents                                       $    1,054,130    $      495,805

  Prepaid expenses and other current assets                               32,613            19,538

  Land use right, current portion                                         15,783            15,783
                                                                  --------------    --------------
      Total Current Assets                                             1,102,526           531,126

NOTE RECEIVABLE, NET OF DISCOUNT                                          38,742            37,893

ADVANCE TO A CONSTRUCTION CONTRACTOR                                          --           362,472

FIXED ASSETS, NET                                                         29,846            18,599

CONSTRUCTIONS IN PROGRESS                                                554,897            81,133

LAND USE RIGHT, NET OF CURRENT PORTION                                   351,461           355,111
                                                                  --------------    --------------

     TOTAL ASSETS                                                 $    2,077,472    $    1,386,334
                                                                  ==============    ==============


                      LIABILITIES AND SHAREHOLDERS' EQUITY
                      ------------------------------------

CURRENT LIABILITIES
  Accrued expenses and other payables                             $      154,965    $       67,143
                                                                  --------------    --------------
      Total current liabilities                                          154,965            67,143
                                                                  --------------    --------------

COMMITMENTS AND CONTINGENCIES                                                 --                --

SHAREHOLDERS' EQUITY
 Common stock, $0.001 par value, 100,000,000 shares
  authorized,
  32,471,537 and 30,271,590 shares issued and
  outstanding, respectively                                               32,472            30,272
 Additional paid-in capital                                            4,093,118         2,995,342
 Prepaid consulting expense                                             (147,090)         (390,890)
 Accumulated other comprehensive income (loss)                            20,890            (1,600)
 Deficit accumulated during the development stage                     (2,076,883)       (1,313,933)
                                                                  --------------    --------------


Total Shareholders' Equity                                             1,922,507         1,319,191

TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY                        $    2,077,472    $    1,386,334
                                                                  ==============    ==============
</TABLE>

The accompanying notes are an integral part of these financial statements.


                                        3
<PAGE>

                    BIO-BRIDGE SCIENCE, INC. AND SUBSIDIARIES
                          (A DEVELOPMENT STAGE COMPANY)
            UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
AND COMPREHENSIVE LOSS FOR THREE MONTHS AND NINE MONTHS ENDED SEPTEMBER 30, 2005
         AND 2004, AND FOR THE PERIOD FROM FEBRUARY 11, 2002 (INCEPTION)
                           THROUGH SEPTEMBER 30, 2005

<TABLE>
<CAPTION>
                                                                                                           For the Period From
                                                                                                            February 11, 2002
                                               Three months ended               Nine months ended          (Inception) Through
                                                   September 30,                   September 30,           September 30, 2005
                                           ----------------------------    ----------------------------    ------------------
                                               2005            2004            2005            2004
                                           ------------    ------------    ------------    ------------
<S>                                        <C>             <C>             <C>             <C>             <C>
REVENUE                                    $         --              --    $         --              --    $               --

Research and development costs                  (39,639)        (34,300)        (60,649)        (42,300)             (201,005)

General and Administrative Expenses            (289,141)       (161,343)       (706,671)       (394,677)           (1,881,206)
                                           ------------    ------------    ------------    ------------    ------------------

LOSS FROM OPERATIONS                           (328,780)       (195,643)       (767,320)       (436,977)           (2,082,211)

OTHER INCOME                                      2,999             270           4,370              78                 7,620

LOSS ON SALE OF INVESTMENT                           --              --              --              --                (2,292)
                                           ------------    ------------    ------------    ------------    ------------------

NET LOSS                                       (325,781)       (195,373)       (762,950)       (436,899)           (2,076,883)

FOREIGN CURRENCY TRANSLATION GAIN (LOSS)         22,490             (23)         22,490              (4)               20,890
                                           ------------    ------------    ------------    ------------    ------------------

COMPREHENSIVE LOSS                         $   (303,291)       (195,396)   $   (740,460)       (436,903)   $       (2,055,993)
                                           ============    ============    ============    ============    ==================

LOSS PER SHARE, BASIC AND DILUTED          $      (0.01)          (0.01)   $      (0.02)          (0.02)
                                           ============    ============    ============    ============

WEIGHTED AVERAGE SHARES OUTSTANDING,
BASIC AND DILUTED                            31,343,714      29,971,590      30,704,441      28,386,684
                                           ============    ============    ============    ============
</TABLE>

The accompanying notes are an integral part of these financial statements.


                                        4
<PAGE>

                    BIO-BRIDGE SCIENCE, INC. AND SUBSIDIARIES
                          (A DEVELOPMENT STAGE COMPANY)
             UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES
          IN SHAREHOLDERS' EQUITY FOR THE PERIOD FROM FEBRUARY 11, 2002
                     (INCEPTION) THROUGH SEPTEMBER 30, 2005

<TABLE>
<CAPTION>
                                                                                                           Deficit
                                                                                         Accumulated     Accumulated
                                                             Additional     Prepaid         Other        During the
                                       Common Stock           Paid-in      Consulting   Comprehensive    Development
                                   Shares        Amount       Capital       Expense          Loss           Stage          Total
                                 -----------  -----------   -----------   -----------    ------------    -----------    -----------
<S>                               <C>         <C>           <C>           <C>             <C>            <C>            <C>
Issuance of 13,750,000
  shares at $0.00004              13,750,000  $    13,750   $   (13,200)   $       --      $       --     $       --    $       550

Issuance of 7,461,090
  shares at $0.0468                7,461,090        7,461       341,719            --              --             --        349,180

Issuance of 1,875,000
  shares at $0.12                  1,875,000        1,875       223,125            --              --             --        225,000

Foreign currency
  translation loss                        --           --            --            --            (499)            --           (499)

  Net loss                                --           --            --            --              --       (114,476)      (114,476)
                                 -----------  -----------   -----------   -----------    ------------    -----------    -----------

BALANCE DECEMBER 31, 2002         23,086,090       23,086       551,644            --            (499)      (114,476)       459,755
------------------------
Issuance of 3,508,425
  shares at $0.12                  3,508,425        3,509       417,502            --              --             --        421,011

Issuance of 201,200 shares
  at $0.32                           201,200          201        64,186            --              --             --         64,387

Foreign currency
  translation loss                        --           --            --            --            (644)            --           (644)

Net loss                                  --           --            --            --              --       (255,020)      (255,020)
                                 -----------  -----------   -----------   -----------    ------------    -----------    -----------

BALANCE DECEMBER 31, 2003         26,795,715       26,796     1,033,332            --          (1,143)      (369,496)       689,489
-------------------------
Issuance of 434,600 shares
  at $0.12                           434,600          435        51,715            --              --             --         52,150

Issuance of 1,125,275
  shares at $0.32                  1,125,275        1,125       358,961            --              --             --        360,086

Issuance of 1,616,000
  shares at $0.5                   1,616,000        1,616       806,382            --              --             --        807,998

Fair market value of Stock
  options granted for services            --           --       695,052            --              --             --        695,052

Fair value of  shares
  issued for services                100,000          100        49,900            --              --             --         50,000

Exercise of options                  200,000          200            --            --              --             --            200

Deferred compensation                     --           --            --      (390,890)             --             --       (390,890)

Foreign currency
  translation loss                        --           --            --            --            (457)            --           (457)

Net loss                                  --           --            --            --              --       (944,437)      (944,437)
                                 -----------  -----------   -----------   -----------    ------------    -----------    -----------

BALANCE DECEMBER 31, 2004         30,271,590       30,272     2,995,342      (390,890)         (1,600)    (1,313,933)     1,319,191
-------------------------

Issuance of 2,179,947
  shares at $0.5 (unaudited)       2,179,947        2,180     1,087,794            --              --             --      1,089,974

Exercise of stock options             20,000           20            --            --              --             --             20

Deferred compensation                                             9,982        (9,982)                                           --

Amortization of deferred
  compensation (unaudited)                --           --            --       253,782              --             --        253,782

Foreign currency
  translation gain (unaudited)            --           --            --            --          22,490             --         22,490

Net loss (unaudited)                      --           --            --            --              --       (762,950)      (762,950)
                                 -----------  -----------   -----------   -----------    ------------    -----------    -----------

BALANCE SEPTEMBER 30, 2005
--------------------------
(unaudited)                       32,471,537  $    32,472   $ 4,093,118   $  (147,090)   $     20,890    $(2,076,883)   $ 1,922,507
----------                       ===========  ===========   ===========   ===========    ============    ===========    ===========
</TABLE>

The accompanying notes are an integral part of these financial statements.


                                        5
<PAGE>

                    BIO-BRIDGE SCIENCE, INC. AND SUBSIDIARIES
                          (A DEVELOPMENT STAGE COMPANY)
            UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
   FOR NINE MONTHS ENDED SEPTEMBER 30, 2005 AND 2004, AND FOR THE PERIOD FROM
            FEBRUARY 11, 2002 (INCEPTION) THROUGH SEPTEMBER 30, 2005

<TABLE>
<CAPTION>
                                                                                          For the Period From
                                                                                           February 11, 2002
                                                              For Nine Months Ended       (Inception) Through
                                                                   September 30,          September 30, 2005
                                                            --------------------------    ------------------
                                                               2005           2004
                                                            -----------    -----------
<S>                                                         <C>            <C>            <C>
CASH FLOWS FROM OPERATING ACTIVITIES
 Net loss                                                   $  (762,950)   $  (436,899)   $       (2,076,883)
 Adjustments to reconcile net loss to net cash used in
operating activities:
 Depreciation                                                     4,871          2,539                10,681
 Amortization of land use right                                   3,650             (4)               27,316
 Amortization of interest income                                   (849)            --                  (849)
 Amortization of prepaid consulting expenses                    253,782             --               557,944
 Stock issued for services                                           --             --                50,550
 Loss on sale of investment                                          --             --                 2,296

 Decrease (increase) in prepaid expenses and other assets       (13,075)       (87,091)             (347,150)
 Increase in accrued expenses and other payables                 87,822         47,047               134,965
                                                            -----------    -----------    ------------------
    Net Cash Used In Operating Activities                      (426,749)      (474,408)           (1,621,130)
                                                            -----------    -----------    ------------------
CASH FLOWS FROM INVESTING ACTIVITIES
 Purchase of land use right                                                         --              (394,559)
 Increase in constructions in progress                         (473,764)       (45,088)             (554,896)
 Purchase of fixed assets                                       (16,118)        (3,994)              (40,528)
 Purchase of investment                                                             --               (40,000)
 Decrease in Advance to a construction contractor               362,472             --               344,348
                                                            -----------    -----------    ------------------
      Net Cash Used In Investing Activities                    (127,410)       (49,082)             (685,635)
                                                            -----------    -----------    ------------------
CASH FLOWS FROM FINANCING ACTIVITIES
 Proceeds from sale of common stock                           1,089,994      1,220,234             3,340,006
                                                            -----------    -----------    ------------------

      Net Cash Provided By Financing Activities               1,089,994      1,220,234             3,340,006
                                                            -----------    -----------    ------------------

 EFFECT OF EXCHANGE RATE CHANGES ON CASH                         22,490              4                20,889
                                                            -----------    -----------    ------------------
NET INCREASE IN CASH AND CASH EQUIVALENTS
                                                                558,325        696,748             1,054,130

 Cash and cash equivalents, beginning of period                 495,805        220,291                    --
                                                            -----------    -----------    ------------------

CASH AND CASH EQUIVALENTS, END OF PERIOD                    $ 1,054,130    $   917,039    $        1,054,130
----------------------------------------                    ===========    ===========    ==================

SUPPLEMENTAL CASH FLOW INFORMATION
 Interest Paid                                              $        --    $        --    $               --
                                                            ===========    ===========    ==================
 Income taxes Paid                                          $        --    $        --    $               --
                                                            ===========    ===========    ==================
Non-Cash investing and financing transactions

Value of options issued
 for deferred compensation                                  $     9,982    $        --    $            9,982
                                                            ===========    ===========    ==================

</TABLE>

The accompanying notes are an integral part of these financial statements.


                                        6
<PAGE>

                    BIO-BRIDGE SCIENCE, INC. AND SUBSIDIARIES
                          (A DEVELOPMENT STAGE COMPANY)
             NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
                       STATEMENTS AS OF SEPTEMBER 30, 2005

NOTE 1 - BASIS OF PRESENTATION

The unaudited condensed consolidated financial statements of Bio Bridge Science
Inc. (the "Company") have been prepared in accordance with generally accepted
accounting principles for interim financial information and pursuant to the
requirements for reporting on Form 10-QSB and Item 310(b) of Regulation S-B.
Accordingly, they do not include all the information and footnotes required by
accounting principles generally accepted in United States of America for
complete financial statements. However, such information reflects all
adjustments (consisting solely of normal recurring adjustments), which are, in
the opinion of management, necessary for the fair presentation of the
consolidated financial position and the consolidated results of operations.
Results shown for interim periods are not necessarily indicative of the results
to be obtained for a full fiscal year. The condensed consolidated balance sheet
information as of December 31, 2004 was derived from the audited consolidated
financial statements included in the Company's Registration Statement Form SB -
2. These interim financial statements should be read in conjunction with that
report.

NOTE 2 - NATURE OF COMPANY

Bio-Bridge Science, Inc. (a development stage company) ("the Company") was
incorporated in the State of Delaware on October 26, 2004 to serve as a vehicle
to effect an exchange of capital stock with Bio-Bridge Science Corporation, a
Cayman Islands corporation, to redomicile from the Cayman Islands to Delaware.
The Company's fiscal year end is December 31.

The Company is a development stage enterprise as defined by Statement of
Financial Accounting Standards (SFAS) No. 7, "Accounting and Reporting by
Development Stage Enterprises." All losses accumulated since the inception of
the Company will be considered as part of the Company's development stage
activities. The Company has not commenced revenue generating activities.

On December 1, 2004, the Company acquired all of the outstanding shares of
Bio-Bridge Science Corporation ("BBSC"), a Cayman Islands corporation, in
exchange for 29,971,590 shares of its common stock, and as a result, BBSC became
a wholly owned subsidiary of Bio-Bridge Science, Inc. BBSC was incorporated in
the Cayman Islands on February 11, 2002. At the time of the exchange, BBSC held
a 100% interest in Bio-Bridge Science (Beijing) Corp. ("BBS Beijing") a
wholly-foreign funded enterprise of the People's Republic of China ("PRC") which
was established on May 20, 2002. Bio-Bridge Science (Beijing) has been issued an
operating license for 25 years, which can be renewed for an additional 25-year
term for a nominal fee. BBS Beijing is currently engaged in the development and
commercialization of the HIV-PV vaccine I in mainland China.

The acquisition was accounted for as a reverse merger (recapitalization) with
Bio-Bridge Science Corporation deemed to be the accounting acquirer, and
Bio-Bridge Science Inc. deemed to be the legal acquirer. Accordingly, the
historical financial information presented in the financial statements is that
of Bio-Bridge Science Corporation as adjusted to give effect to any difference
in the par value of the issuer's and the accounting acquirer's stock with an
offset to capital in excess of par value. The basis of the assets, liabilities
and retained earnings of BBSC, the accounting acquirer, have been carried over
in the recapitalization.

NOTE 3 - GOING CONCERN

The accompanying condensed consolidated financial statements have been prepared
on the basis that the Company will continue as a going concern which assumes the
realization of assets and settlement of liabilities in the normal course of
business. Since its inception, the Company has been engaged in organizational
and pre-operating activities. Furthermore, the Company has generated no revenue
and has incurred accumulated losses and negative operating cash flows of
$2,076,883 and $1,621,130, respectively, since inception. Continuation of the
Company's existence is dependent upon its ability to obtain additional capital
and sustain profitable operations.


                                       7
<PAGE>

The uncertainty related to these conditions raises substantial doubt about the
Company's ability to continue as going concern. The accompanying condensed
consolidated financial statements do not include any adjustments that might
result from the outcome of this uncertainty.

During the next 12 months, the Company intends to raise capital through an
offering of its securities or from loans to continue research and development of
HIV-PV Vaccine I in China as well as complete the construction of its laboratory
in China. The Company has no current arrangements for obtaining the additional
cash and working capital it may require, and will seek to raise it through the
public or private sales of its securities, or loans, or a combination of the
foregoing. The Company cannot guarantee financing will be available, on
acceptable terms or at all. At this time, the Company is unable to determine
when the HIV-PV Vaccine I will become fully developed manufactured and sold. The
Company does not expect to generate any significant revenues in the next 12
months. If the Company fails to obtain other financing, either through an
offering of our securities or by obtaining additional loans, we may be unable to
maintain our operations.

NOTE 4 - ECONOMIC AND POLITICAL RISKS

The Company faces a number of risks and challenges since its operation is in PRC
and its primary market is in the PRC. We have operations in China. Most of the
pre-clinical testing of our HIV-PV Vaccine I product on laboratory animals in
Beijing, China was completed in October 2005. Our business operations may be
adversely affected by the political environment in the PRC. The PRC has operated
as a socialist state since 1949 and is controlled by the Communist Party of
China. In recent years, however, the government has introduced reforms aimed at
creating a "socialist market economy" and policies have been implemented to
allow business enterprises greater autonomy in their operations. Changes in the
political leadership of the PRC may have a significant effect on laws and
policies related to the current economic reforms program, other policies
affecting business and the general political, economic and social environment in
the PRC, including the introduction of measures to control inflation, changes in
the rate or method of taxation, the imposition of additional restrictions on
currency conversion and remittances abroad, and foreign investment. These
effects could substantially impair our business, profits or prospects in China.
Moreover, economic reforms and growth in the PRC have been more successful in
certain provinces than in others, and the continuation or increases of such
disparities could affect the political or social stability of the PRC.

NOTE 5 - USE OF ESTIMATES

The preparation of the condensed consolidated financial statements in conformity
with generally accepted accounting principles requires management to make
estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of
the condensed consolidated financial statements, and expenses during the
reporting periods. Actual results when ultimately realized could differ from
those estimates.

NOTE 6 - LOSS PER SHARE

Basic loss per share has been computed using the weighted average number of
common shares outstanding during the corresponding periods. Diluted loss per
share is computed based on the weighted average number of common shares and all
common equivalent shares outstanding during the periods in which they are
dilutive. Common equivalent shares consist of shares issuable upon the exercise
of stock options (using the treasury stock method) or warrants. As of September
30, 2005 common stock equivalents consist of 1,192,675 options that each convert
into one share of the Company's common stock. For the three months and nine
months ended September 30, 2005 and 2004, common equivalent shares have been
excluded from the calculation of loss per share as their effect is
anti-dilutive.


                                       8
<PAGE>

NOTE 7 - FAIR VALUE OF FINANCIAL INSTRUMENTS

The carrying value of financial instruments including cash and cash equivalents,
note receivable, prepaid expenses and other current assets, accrued expenses and
other payables, approximates their fair value at September 30, 2005 and December
31, 2004 due to the relatively short-term nature of these instruments.

NOTE 8 - FOREIGN CURRENCY CONVERSION

The Company's financial information is presented in US dollars. The functional
currency Renminbi (RMB) of the Company is translated into United States dollars
from RMB at quarter / year-end exchange rates as to assets and liabilities and
average exchange rates as to revenues and expenses. Capital accounts are
translated at their historical exchange rates when the capital transactions
occurred.

                                                  2005      2004
                                                 ------    ------
Quarter / Year end RMB : US$ exchange rate       8.0920    8.2765
Average yearly RMB : US$ exchange rate           8.1843    8.2766

The RMB is not freely convertible into foreign currency and all foreign exchange
transactions must take place through authorized institutions. No representation
is made that the RMB amounts could have been, or could be, converted into US
dollars at the rates used in translation.

On July 22, 2005, Renminbi rose approximately 2 percent against the US dollar at
the exchange rate of 8.11 to 1.

NOTE 9 - SHAREHOLDER'S EQUITY

The following represents transactions involving the purchases of the Company's
common stock for cash categorized by period (for the period from the date of
inception to September 30, 2005):

2002:

    ISSUANCE OF 13,750,000 SHARES AT $0.00004 FOR TOTAL CONSIDERATION OF $550

o     At inception, 13,750,000 shares of common stock were issued for a total
      cash payment of $550.

      ISSUANCE OF 7,461,090 SHARES AT $0.0468 FOR TOTAL CONSIDERATION OF
      $349,180

o     On July 15, 2002, 1,675,000 shares were issued to two individuals for a
      total cash payment of $78,390.

o     On July 19, 2002, 2,125,000 shares were issued for a cash payment of
      $99,450.

o     On June 27, 2002, 786,090 shares were issued for a cash payment of
      $36,790.


                                       9
<PAGE>

o     On November 8, 2002, 2,875,000 shares were issued to 9 individuals for a
      total cash payment of $134,550.

    ISSUANCE OF 1,875,000 SHARES AT $0.12 FOR TOTAL CONSIDERATION OF $225,000

o     On September 6, 2002, 375,000 shares of common stock were issued for a
      cash payment of $45,000.

o     On November 8, 2002, 250,000 shares were issued for a cash payment of
      $30,000.

o     On November 12, 2002, 1,250,000 shares were issued to five individuals for
      a total cash payment of $150,000. 2003:

    ISSUANCE OF 3,508,425 SHARES AT $0.12 FOR TOTAL CONSIDERATION OF $421,011

o     On July 14, 2003, 250,000 shares were issued for a cash payment of
      $30,000.

o     On July 28, 2003, 75,000 shares were issued for a cash payment of $9,000.

o     On July 29, 2003, 291,750 shares were issued for a cash payment of
      $35,010.

o     On August 7, 2003, 50,000 shares were issued to two individuals for a
      total cash payment of $6,000.

o     On September 2, 2003, 125,000 shares were issued for a cash payment of
      $15,000.

o     On September 3, 2003, 1,500,000 shares were issued for a cash payment of
      $180,000.

o     On September 12, 2003, 83,350 shares were issued for a cash payment of
      $10,001.

o     On November 5, 2003, 883,325 shares were issued to two individuals for a
      total cash payment of $106,000.

o     On December 31, 2003, 250,000 shares were issued for $30,000. This amount
      was recorded as subscription receivable by the Company as of December 31,
      2003 and subsequently collected on January 5, 2004.

     ISSUANCE OF 201,200 SHARES AT $0.32 FOR TOTAL CONSIDERATION OF $64,387

o     On October 20, 2003, 93,750 shares were issued to two individuals for a
      total cash payment of $30,000.

o     On November 5, 2003, 28,025 shares were issued for a cash payment of
      $8,977.

o     On November 6, 2003, 25,000 shares were issued for a cash payment of
      $8,000.

o     On November 12, 2003, 23,175 shares were issued to three individuals for a
      total cash payment of $7,410.

o     On December 18, 2003, 31,250 shares were issued for a cash payment of
      $10,000.

NOTE 9 - SHAREHOLDER'S EQUITY (CONTINUED)

2004:

     ISSUANCE OF 434,600 SHARES AT $0.12 FOR TOTAL CONSIDERATION OF $52,150

o     On March 25, 2004, 434,600 shares were issued to three individuals for a
      total cash payment of $52,150.

   ISSUANCE OF 1,125,275 SHARES AT $0.32 FOR TOTAL CONSIDERATION OF $360,086

o     On January 26, 2004, 12,500 shares of common stock were issued for a cash
      payment of $4,000.

o     On January 30 2004, 14,750 shares were issued for a cash payment of
      $4,720.

o     On February 18, 2004, 31,250 shares were issued for a cash payment of
      $10,000.

o     On March 5, 2004, 14,175 shares were issued for a cash payment of $4,540.

o     On March 15, 2004, 23,375 shares were issued to three individuals for a
      total cash payment of $7,480.

o     On March 17, 2004, 15,625 shares were issued for a cash payment of $5,000.

o     On March 26, 2004, 46,875 shares were issued to two individuals for a
      total cash payment of $15,000.

o     On March 31, 2004, 31,250 shares were issued for a cash payment of
      $10,000.

o     On April 2, 2004, 31,250 shares were issued for a cash payment of $10,000.

o     On April 6, 2004, 31,250 shares were issued for a cash payment of $10,000.


                                       10
<PAGE>

o     On April 28, 2004, 57,500 shares were issued for a cash payment of
      $18,400.

o     On April 30, 2004, 251,725 shares were issued to ten individuals for a
      total cash payment of $80,546.

o     On May 11, 2004, 50,000 shares were issued to two individuals for a total
      cash payment of $16,000.

o     On May 15, 2004, 13,750 shares were issued for a cash payment of $4,400.

o     On May 28, 2004, 500,000 shares were issued for a cash payment of
      $160,000.

    ISSUANCE OF 1,616,000 SHARES AT $0.50 FOR TOTAL CONSIDERATION OF $807,998

o     On May 31, 2004, 20,000 shares were issued for a cash payment of $10,000.

o     On June 1, 2004, 240,000 shares were issued to three individuals for a
      total cash payment of $120,000.

o     On June 4, 2004, 85,000 shares were issued to four individuals for a total
      cash payment of $42,498.

o     On June 5, 2004, 81,000 shares were issued to three individuals for a
      total cash payment of $40,500.

o     On June 7, 2004, 80,000 shares were issued to four individuals for a total
      cash payment of $40,000.

o     On June 8, 2004, 40,000 shares were issued to two individuals for a total
      cash payment of $20,000.

o     On June 9, 2004, 60,000 shares were issued to two individuals for a total
      cash payment of $30,000.

o     On June 11, 2004, 140,000 shares were issued to six individuals for a
      total cash payment of $70,000.

o     On June 12, 2004, 60,000 shares were issued to two individuals for a total
      cash payment of $30,000.

o     On June 13, 2004, 20,000 shares were issued for a cash payment of $10,000.

o     On June 14, 2004, 260,000 shares were issued to nine individuals for a
      total cash payment of $130,000.

o     On June 15, 2004, 530,000 shares were issued to twelve individuals for a
      total cash payment of $265,000.

                        Other Capital Stock Transactions

On December 1, 2004, the Company issued 100,000 shares of its common stock and
an option to purchase an additional 50,000 shares of its common stock at $.001
per share to Richardson & Patel, LLC in consideration for legal services. The
shares issued were valued at $50,000, their fair value at the date of issuance.
The options granted were valued at $24,954 at the date of grant, which was
determined by the Black-Scholes valuation method, using the following
assumptions: no expected dividend yield; risk-free interest rates of 3.4%;
expected lives of 3 years; and estimated volatility of 85 percent based on
recent history of the stock price in the industry.

On December 1, 2004, 200,000 shares of common stock were issued at $0.001 per
share for a cash payment of $200 from an exercise of stock options.

2005:

   ISSUANCE OF 2,179,947 SHARES AT $0.5 FOR TOTAL CONSIDERATION OF $1,089,974

o     On April 22, 2005, 20,000 shares were issued to one individual for a total
      cash payment of $10,000.

o     On May 9, 2005, 100,000 shares were issued to one individual for a cash
      payment of $50,000.

o     On May 10, 2005, 100,000 shares were issued to one individual for a cash
      payment of $50,000.

o     On May 20, 2005, 100,000 shares were issued to one individual for a total
      cash payment of $50,000.

o     On June 6, 2005, 60,000 shares were issued to one individual for a total
      cash payment of $30,000.

o     On June 13, 2005, 50,000 shares were issued to two individuals for a total
      cash payment of $25,000.

o     On June 15, 2005, 40,000 shares were issued to one individual for a total
      cash payment of $20,000.

o     On June 20, 2005, 100,000 shares were issued to two companies for a total
      cash payment of $50,000.

o     On August 23, 2005, 30,000 shares were issued to two individuals for a
      total cash payment of $15,000.

o     On August 26, 2005, 60,000 shares were issued to three individuals for a
      total cash payment of $30,000.

o     On August 29, 2005, 130,000 shares were issued to five individuals for a
      total cash payment of $65,000.

o     On August 30, 2005, 116,250 shares were issued to three individuals for a
      total cash payment of $58,125.

o     On August 31, 2005, 766,046 shares were issued to twenty-five individuals
      for a total cash payment of $383,023.

o     On September 5, 2005, 40,000 shares were issued to one individual for a
      total cash payment of $20,000.

o     On September 12, 2005, 352,651 shares were issued to one individual for a
      total cash payment of $176,326.

o     On September 22, 2005, 100,000 shares were issued to one individual for a
      total cash payment of $50,000.

o     On September 23, 2005, 15,000 shares were issued to one individual for a
      total cash payment of $7,500.


                                       11
<PAGE>

EXERCISE OF 20,000 STOCK OPTIONS AT $0.001 FOR TOTAL CONSIDERATION OF $20

o     On July 1, 2005, 20,000 stock options were exercised by two individuals
      for a total cash payment of $20.

Other Capital Stock Transactions

On December 1, 2004, the Company issued to Columbia China Capital Group, Inc. an
option to purchase 1,342,675 shares of common stock at $.001 per share to be
exercised within a three-year period in consideration for financial consulting
services to be provided over a two year period. The options granted were granted
outside the Company's stock option plan. On December 1, 2004, 200,000 of these
options were exercised. The options were valued at their fair value of $670,098
at the date of grant, which was determined by the Black-Scholes valuation method
using the following assumptions: no expected dividend yield; risk-free interest
rates of 3.4%; expected lives of 3 years; and estimated volatility of 85% based
on recent history of the stock price in the industry. The value of the options
issued was capitalized by the company as a prepaid consulting fee and is being
amortized over the two year term of the service agreement. During the year ended
September 30, 2005, $530,494 of this amount was amortized and included in the
accompanying statement of operations, and the remaining unamortized amount of
$139,604 was reflected as prepaid consulting costs in the accompanying balance
sheet as of September 30, 2005. The option values will be recalculated at the
end of each quarter until the services are complete. As such, the amounts
required to be expensed may vary from the original amount.

On December 1, 2004, the Company issued 100,000 shares of its common stock and
an option to purchase an additional 50,000 shares of its common stock at $.001
per share to Richardson & Patel, LLC in consideration for legal services. The
shares issued were valued at $50,000, their fair value at the date of issuance.
The options granted were valued at $24,954 at the date of grant, which was
determined by the Black-Scholes valuation method, using the following
assumptions: no expected dividend yield; risk-free interest rates of 3.4%;
expected lives of 3 years; and estimated volatility of 85 percent based on
recent history of the stock price in the industry.

On December 1, 2004, 200,000 shares of common stock were issued at $0.001 per
share for a cash payment of $200 from an exercise of stock options.

On July 1, 2005, the Company issued to two individual consultants an option to
purchase 20,000 shares of common stock at $.001 per share to be exercised within
a three-year period in consideration for scientific advisory service to be
provided over a one-year period, and all of these shares were exercised at the
same time when they were granted. The options granted were valued at $9,982 at
the date of grant, which was determined by the Black-Scholes valuation method,
using the following assumptions: no expected dividend yield; risk-free interest
rates of 3.4%; expected lives of 3 years; and estimated volatility of 85 percent
based on recent history of the stock price in the industry. The value of the
options issued was capitalized by the company as a prepaid consulting fee and is
being amortized over the one year term of the service agreement.

During the nine months ended September 30, 2005, $253,782 of this amount was
amortized and included in the accompanying statement of operations, and the
remaining unamortized amount of $147,090 was reflected as prepaid consulting
costs in the accompanying statement of changes in shareholders' equity as of
September 30, 2005. The option values are recalculated at the end of each
quarter until the services are complete. During the nine months ended September
30, 2005, there have been new issuances of 1,629,947 shares of common stock at
$0.5 per share. All the external conditions and assumptions used in the
Black-Scholes valuation method remain unchanged. Therefore the Company believes
there is no change in the valuation of the carrying stock options as of
September 30, 2005.

NOTE 10 - COMMITMENTS AND CONTINGENCIES

Construction commitment

In May 2003, the Company acquired a land use right for approximately 2.8 acres
of land in the Tianzhu Export Processing Zone, Shunyi District, Beijing, China,
which the Company plans to develop into a laboratory and biomanufacturing
facility in compliance with Good Manufacturing Practices, or GMP, regulations
primarily for clinical trials of HIV-PV Vaccine I. As of September 30, 2005, the
Company has received all necessary permits and approvals and construction of the
facility had commenced. The outside main body of the GMP laboratory has been
completed as of September 30, 2005. The Company has entered into a construction
contract relating to the completion for this facility. As of September 30, 2005
a payment of $362,472 has been made to this contractor, and has a further
outstanding commitment under this contract of $362,472, of which $61,789 has
been accrued and is included in accrued expenses as of September 30, 2005. The
Company estimates that the cost of the building and outfitting of this facility
is $3,000,000, and the construction and installation of equipment related to the
facility will be substantially completed by December 2005.

Item 2. Management's Discussion and Analysis or Plan of Operation

Some of the statements made by us in this Quarterly Report on Form 10-QSB are
forward-looking in nature, including but not limited to, statements relating to
our future revenue and expenses, product development, future market acceptance,
levels of research and development, our management's plans and objectives for
our current and future operations, and other statements that are not historical
facts. Forward-looking statements include, but are not limited to, statements
that are not historical facts, and statements including forms of the words
"intend", "believe", "will", "may", "could", "expect", "anticipate", "plan",
"possible", and similar terms. Actual results could differ materially from the
results implied by the forward looking statements due to a variety of factors,
many of which are discussed throughout this Quarterly Report and in our SEC
filings. Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. We undertake
no obligation to publicly release any revisions to these forward-looking
statements that may reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events, unless required by law. Factors
that could cause actual results to differ materially from those expressed in any
forward-looking statement made by us include, but are not limited to:

o     our ability to finance our activities and maintain our financial
      liquidity;

o     our ability to attract and retain qualified, knowledgeable employees;

o     our ability to complete product development;

o     our ability to obtain regulatory approvals to conduct clinical trials;

o     our ability to design and market new products successfully;

o     our failure to acquire new customers in the future;

o     deterioration of business and economic conditions in our markets;

o     intensely competitive industry conditions; and

In this document, the words "we," "our," "ours," and "us" refers to Bio-Bridge
Science, Inc. and our wholly owned subsidiaries, including Bio-Bridge Science
(Beijing) Co. Ltd., a Wholly-Foreign Funded Enterprise of the People's Republic
of China ("Bio-Bridge (Beijing)") and Bio-Bridge Science Corporation, a Cayman
Islands corporation.


                                       12
<PAGE>

Overview

Bio-Bridge Science, Inc. is a development stage company whose subsidiaries are
focused on the commercial development of HIV-PV Vaccine I technology. Most of
the pre-clinical testing of HIV-PV Vaccine I on laboratory animals in Beijing,
China was completed in October 2005. Once the pre-clinical testing is completed
and the laboratory inner purified environment decoration project is finished, we
will apply to China's State Food and Drug Administration for approval to conduct
clinical trials of HIV-PV Vaccine I. As of September 30, 2005, we have completed
the construction of the outside body of our laboratory and biomanufacturing
facility in Beijing, China.

Since inception, we have generated no revenues. We incurred net losses of
$944,437 in 2004 and $255,020 in 2003. As of September 30, 2005, we had an
accumulated deficit of $2,076,883. Our continued existence is dependent upon our
ability to obtain additional financing. Our capital requirements for the next 12
months, as they relate to further research and development relating to our
product candidate, HIV-PV Vaccine I, have been and will continue to be
significant. As of September 30, 2005, we have funded our operations through
equity offerings whereby we raised an aggregate $3,340,006 since inception. We
will need to obtain additional financing in addition to the funding already
raised through the sale of equity securities to fund our cash needs and continue
our operations beyond August 2006. From April 22, 2005 to date, we have sold
shares pursuant to private placements, and have raised gross proceeds of
$1,089,974. As of December 31, 2004, our independent auditors have added an
explanatory paragraph to their report of our audited financial statements for
the year ended December 31, 2004 stating that our net loss of $944,437, lack of
revenues and dependence on our ability to raise additional capital to continue
our existence, raise substantial doubt about our ability to continue as a going
concern. Our consolidated financial statements and their explanatory notes
included as part of this quarterly report do not include any adjustments that
might result from the outcome of this uncertainty. If we fail to obtain
additional financing, either through an offering of our securities or by
obtaining loans, we may be forced to reduce operating costs and postpone
completion of our laboratory and manufacturing facility. Development of our
vaccine would likely be adversely affected or suspended altogether from such
cost reductions, and we may be forced to cease our business.

Plan of Operation

Our primary corporate focus is on the commercial development of HIV-PV Vaccine I
through our subsidiaries. Our capital requirements, particularly as they relate
to product research and development, have been and will continue to be
significant. Our future cash requirements and the adequacy of available funds
will depend on many factors, including the pace at which we are able to obtain
regulatory approvals of HIV-PV Vaccine I, whether or not a market develops for
our products and, if a market develops, the pace at which it develops, and the
pace at which the technology involved in making our products changes.

To date, our wholly owned subsidiary, Bio-Bridge Science Corporation, has funded
its activities through private equity financings. During the next 12 months, we
need to raise capital through an offering of our securities or from loans to
continue research and development of HIV-PV Vaccine I in China as well as
complete the construction of our laboratory in China, which we estimate will
cost approximately $3 million, of which approximately $2,000,000 remains to be
funded as of September 30, 2005. From April 22, 2005 to September 30, 2005, we
issued 2,179,947 shares of common stock at a price per share of $0.50 to 52
investors pursuant to private placements, and raised gross proceeds of
$1,089,974. We currently have no commitments to make payments for this
construction project, except for $362,472 pursuant to a contract involving
structural and foundation work for the facility. We estimate that our capital
requirements for the next 12 months will be as follows:

o     approximately $2,600,000 for our laboratory/biomanufacturing facility
      inner purified environment decoration project and electricity work
      project;

o     approximately $800,000 to purchase advanced laboratory equipment for our
      vaccine study;

o     approximately $500,000 to finish Phase I clinical study and the
      preparatory work; and

o     approximately $800,000 for working capital and general corporate needs.


                                       13
<PAGE>

In addition, we estimate that the total cost to bring our product to market in
China will be $10 million for the therapeutic vaccine, and an additional $6
million to bring the preventative vaccine to market. We believe that the
therapeutic vaccine can be brought to market within three years and the
preventative vaccine can be brought to market within five to seven years, if we
are successful in raising the funds to complete development of the vaccine.

As of September 30, 2005, our cash and cash equivalents position was $1,054,130,
which we expect will fund our operations through August 2006. Although we
recently have raised gross proceeds of $1,089,974 pursuant to private equity
financings, we will need to raise additional funds through the public or private
sales of our securities, or loans, or a combination of the foregoing. We cannot
guarantee that financing will be available to us, on acceptable terms or at all.
We also may borrow from the local bank in China given that we own our land use
right that could be used as collateral for borrowing. We do not expect to
generate any significant revenues in the next 12 months. If we fail to obtain
other financing, either through an offering of our securities or by obtaining
additional loans, we may be unable to maintain our operations and may be forced
to cease our business.

Results of Operations

Three Months Ended September 30, 2005 Compared to Three Months Ended September
30, 2004

During the quarters ended September 30, 2005 and 2004, we had no revenue. We do
not expect to have significant revenues relating to our product candidates in
development prior to 2007.

For the quarter ended September 30, 2005, research and development expense was
$39,639 as compared to $34,300 for the third quarter of 2004. The increase of
$5,339 is due primarily to an increase of research and development staff.

For the quarter ended September 30, 2005, general and administrative expense was
$289,141 as compared to $161,343 for the quarter ended September 30, 2004. The
increase of $127,798 is primarily due to increase in salary and consulting fees
of approximately of $31,300, and $85,000 individually. In addition, we had
increases in expenses related to rent and all other expense of $8,500 and
$2,998, respectively.

For the quarter ended September 30, 2005, interest and other income was $2,999
as compared to $270 for the quarter ended September 30, 2004. The increase of
$2,729 is due primarily to an increase in cash balances.

Net loss for the quarter ended September 30, 2005, was $325,781 as compared to
$195,643 for the quarter ended September 30, 2004. This increase in net loss is
attributable primarily to the above-mentioned salary increase and an increase of
consulting related fees.

Nine Months Ended September 30, 2005 Compared to Nine Months Ended September 30,
2004

During the nine months ended September 30, 2005 and 2004, we had no revenue. We
do not expect to have significant revenues relating to our product candidates in
development prior to 2007.

For the nine months ended September 30, 2005, research and development expense
was $60,649 as compared to $42,300 for the nine months ended September 30, 2004.
The increase of $18,349 is due primarily to an increase of research and
development staff and cost


                                       14
<PAGE>

For the nine months ended September 30, 2005, general and administrative expense
was $706,671 as compared to $394,677 for the nine months ended September 30,
2004. The increase of $311,994 is due primarily to increases in consulting fees
and salary expenses of approximately $195,600 and $75,300 respectively. In
addition we had increases in expenses related to rent, travel and all other
expenses of $30,500 $6,200 and $4,394, respectively.

For the nine months ended September 30, 2005, interest and other income (loss)
was $4,370 as compared to $78 for the nine months ended September 30, 2004. The
increase of $4,292 is due primarily to an increase in cash balances.

Net loss for the nine months ended September 30, 2005, was $762,950 as compared
to $436,899 for the nine months ended September 30, 2004. This increase in net
loss is attributable primarily to the above-mentioned salary, rent increase and
an increase of consulting related fees.

Liquidity and Capital Resources

Our principal sources of liquidity are cash and cash equivalent balances, which
were $1,054,130 at September 30, 2005 and $495,805 at December 31, 2004. Since
our inception, we have incurred significant losses, and as of September 30, 2005
we had an accumulated deficit of $2,076,883.

Net cash used in operating activities was $426,749 for the nine months ended
September 30, 2005 and $474,408 for the nine months ended September 30, 2004.

Cash flows used in investing activities was $127,410 for the nine months ended
September 30, 2005 and $49,082 for the nine months ended September 30, 2004.
This change was from purchase fixed assets and construction in process.

Net cash provided by financing activities decreased to $1,089,994 in the first
nine months ended September 30, 2005 compared to $1,220,234 in the first nine
months ended September 30, 2004.

To date, our operations have been funded through issuances of our common stock
whereby we raised an aggregate $3,340,006 from inception through September 30,
2005.

Based on our current operating plan we believe that we have sufficient cash and
cash equivalents to last approximately through August 2006. We will need to
obtain additional financing in addition to the funds already raised through the
sale of equity securities to fund our cash needs and continue our operations
beyond August 2006. Additional financing, whether through public or private
equity or debt financing, arrangements with stockholders or other sources to
fund operations, may not be available, or if available, may be on terms
unacceptable to us. Our ability to maintain sufficient liquidity is dependent on
our ability to raise additional capital. If we issue additional equity
securities to raise funds, the ownership percentage of our existing stockholders
would be reduced. New investors may demand rights, preferences or privileges
senior to those of existing holders of our common stock. Debt incurred by us
would be senior to equity in the ability of debt holders to make claims on our
assets. The terms of any debt issued could impose restrictions on our
operations. If adequate funds are not available to satisfy either short or
long-term capital requirements, our operations and liquidity could be materially
adversely affected and we could be forced to cease operations.

Critical Accounting Policies

Our discussion and analysis of our financial condition and results of operations
are based on our consolidated financial statements, which have been prepared in
accordance with accounting principles generally accepted in the U.S. The
preparation of these financial statements requires us to make estimates and
judgments that affect the reported amounts of assets, liabilities, revenues and
expenses for each period. The following represents a summary of our critical
accounting policies, defined as those policies that we believe are the most
important to the portrayal of our financial condition and results of operations
and that require management's most difficult, subjective or complex judgments,
often as a result of the need to make estimates about the effects of matters
that are inherently uncertain.


                                       15
<PAGE>

Stock compensation costs. We account for stock-based compensation issued to
employees using the intrinsic-value method prescribed in Accounting Principles
Board Opinion (APB) No. 25, "Accounting for Stock Issued to Employees." We
account for stock option and warrant grants issued to non-employees using the
guidance of SFAS No. 123, "Accounting for Stock-Based Compensation" and EITF No.
96-18: "Accounting for Equity Instruments that are Issued to Other Than
Employees for Acquiring, or in Conjunction with Selling, Goods or Services,"
whereby the fair value of such option and warrant grants is determined using the
Black-Scholes option pricing model at the date of grant.

In December 2004, the FASB issued SFAS No. 123(R), "Share-Based Payment". This
Statement revises FASB Statement No. 123, "Accounting for Stock-Based
Compensation" and supersedes APB Opinion No. 25, "Accounting for Stock Issued to
Employees". SFAS No. 123(R) focuses primarily on the accounting for transactions
in which an entity obtains employee services in share-based payment
transactions. SFAS No. 123(R) requires companies to recognize in the statement
of operations the cost of employee services received in exchange for awards of
equity instruments based on the grant-date fair value of those awards (with
limited exceptions). This Statement is effective as of the first fiscal year
reporting period that begins after June 15, 2005 for large business issuers and
December 15, 2005 for small business issuers. 123R offers us alternative methods
of adoption of this standard. At the present time, we have not yet determined
which alternative method we will use and the resulting impact on our financial
position or results of operations.

Impairment of long-lived assets. We account for long-lived assets in accordance
with Statement of Financial Accounting Standards No. 144, Accounting for the
Impairment or Disposal of Long-Lived Assets, or SFAS No. 144, which was adopted
on January 1, 2002. SFAS No. 144 supersedes Statement of Financial Accounting
Standards No. 121, Accounting for the Impairment of Long-Lived Assets and for
Long- Lived Assets To Be Disposed of, or SFAS No. 121. Our long-lived assets
consist of land use right, notes, fixed assets, construction in process, and
prepaid consulting fees. We regularly evaluate our long-lived assets, including
our intangible assets, for indicators of possible impairment whenever events or
changes in business circumstances indicate that the carrying amount of the
assets may not be fully recoverable. An impairment loss would be recognized when
estimated undiscounted future cash flows expected to result from the use of an
asset and its eventual disposition are less than its carrying amount.
Impairment, if any, is measured using discounted cash flows. In the years ending
December 31, 2004 and 2003, we performed an evaluation of our long-lived assets
and noted no impairment.

Item 3. Controls and Procedures

(a) Evaluation of disclosure controls and procedures. As of the end of the
period covered by this report, we carried out an evaluation, under the
supervision and with the participation of our management, including our Chief
Executive Officer and Chief Financial Officer, of the effectiveness of the
design and operation of our disclosure controls and procedures, as defined in
Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as
amended. Based upon that evaluation, our Chief Executive Officer and Chief
Financial Officer concluded that our disclosure controls and procedures were
effective as of the end of the applicable period to ensure that the information
required to be disclosed by us in reports that we file or submit under the
Exchange Act (i) is recorded, processed, summarized and reported within the time
periods specified in Securities and Exchange Commission rules and forms and (ii)
is accumulated and communicated to our management, including our Chief Executive
Officer and Chief Financial Officer, as appropriate to allow timely decisions
regarding required disclosures.

(b) Changes in internal controls over financial reporting. There was no change
in our internal control over financial reporting during our most recent fiscal
quarter that has materially affected, or is reasonably likely to materially
affect, our internal control over financial reporting.


                                       16
<PAGE>

                           PART II - OTHER INFORMATION

Item 1. Legal Proceedings

Not Applicable

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

During the third quarter 2005, we issued 1,494,947 shares of common stock at a
price per share of $.50 to 40 investors in reliance upon the exemption from
registration set forth in Regulation S under the Securities Act of 1933, as
amended (the "Act"), and raised gross proceeds of $747,474. We did not conduct a
public solicitation in connection with the offer, purchase or sale of these
shares, no advertisement was conducted with respect to this issuance in any
public medium or forum, and we offered the shares on our behalf only to
investors who resided outside the U.S. and were not a "U.S. person", as defined
in Regulation S under the Act, nor did they acquire the shares for the account
or benefit of a U.S. person. The following conditions were all met with respect
to the shares issued in the transaction: (1) the investors acknowledged that the
shares have not been registered under the Act and that they may not be offered,
sold or transferred, except in compliance with the Act and other applicable laws
or an exemption therefrom, (2) the investors were sufficiently aware of the
registrant's business affairs and financial condition to reach an informed
decision to acquire the registrant's shares, and (3) neither the registrant nor
the investor paid any fees to any finder or broker-dealer in conjunction with
this issuance.

On July 1, 2005, we issued to two individual consultants an option to purchase
20,000 shares of common stock at $.001 per share to be exercised within a
three-year period in consideration for scientific advisory service to be
provided over a one-year period, and all of these shares were exercised at the
same time when they were granted for total cash consideration of $20. The
options granted were valued at $9,982 at the date of grant, which was determined
by the Black-Scholes valuation method, using the following assumptions: no
expected dividend yield; risk-free interest rates of 3.4%; expected lives of 3
years; and estimated volatility of 85 percent based on recent history of the
stock price in the industry. The value of the options issued was capitalized by
us as a prepaid consulting fee and is being amortized over the one year term of
the service agreement. These transactions were made in reliance upon the
exemption from registration set forth in Section 4(2) of the Act. The following
conditions were all met with respect to this transaction: (1) we did not
advertise this issuance in any public medium or forum, (2) we did not solicit
any investors with respect to this issuance, (3) we did not publicize any
portion of the purchase or sale of the shares issued, (4) none of the shares
issued were offered in conjunction with any public offering, (5) neither we nor
the investors paid any fees to any finder or broker-dealer in conjunction with
this issuance.

In September 2005, we issued 115,000 shares of common stock at a price per share
of $.50 to two investors in reliance upon the exemption from registration set
forth in Section 4(2) of the Act, and raised gross proceeds of $57,500. The
following conditions were all met with respect to this transaction: (1) we did
not advertise this issuance in any public medium or forum, (2) we did not
solicit any investors with respect to this issuance, (3) we did not publicize
any portion of the purchase or sale of the shares issued, (4) none of the shares
issued were offered in conjunction with any public offering, (5) neither we nor
the investors paid any fees to any finder or broker-dealer in conjunction with
this issuance.

Item 3. Defaults Upon Senior Securities

Not Applicable

Item 4. Submission of Matters to a Vote of Security Holders

Not Applicable

Item 5. Other Information

Not applicable

Item 6. Exhibits

The exhibits listed in the Exhibit Index are filed as part of this report.


                                       17
<PAGE>

                                   SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.

                            Bio-Bridge Science, Inc.



/s/ Dr. Liang Qiao
---------------------------
By: Dr. Liang Qiao                            Dated: November 14, 2005
    Chief Executive Officer


                                       18
<PAGE>

                                  EXHIBIT INDEX



2.1*        Agreement for the exchange of shares by and among the registrant,
            Bio-Bridge Science Corporation and the shareholders of record of
            Bio-Bridge Science Corporation, dated November 4, 2004

3.1(i)*     Certificate of incorporation of the registrant, as currently in
            effect

3.1(ii)*    Bylaws of the registrant, as currently in effect

10.1*       Exclusive License Agreement between Bio-Bridge Science Corporation
            and Loyola University Chicago, dated April 22, 2004

10.2*       Exclusive Sub-license Agreement between Beijing Bio-Bridge Science
            Corporation and Beijing Bio-Bridge Science Corporation, dated June
            20, 2002

10.3*       2004 stock incentive plan

10.4*       Lease between Bio-Bridge Science Corporation and SFERS Real Estate K
            Limited Partnership, dated July 30, 2004

10.5*       Agreement between Bio-Bridge Beijing Science Corporation and Beijing
            Institute of Radiation Medicine, dated May 6, 2004

10.6*       Land Use Right Agreement between Bio-Bridge Science (Beijing) Co.
            Ltd. and Beijing Airport High-Tech Park Co. Ltd., dated May 28,
            2003.

10.7*       Agreement between Bio-Bridge Beijing Science Corporation and Beijing
            Institute of Radiation Medicine, dated May 12, 2004.

21.1*       List of subsidiaries

31.1        Certification of Chief Executive Officer

31.2        Certification of Chief Financial Officer

32.1        Section 1350 Certifications of Chief Executive Officer and Chief
            Financial Officer



* Previously filed with the Securities and Exchange Commission pursuant to
Registration Statement No. 333-121786.


                                       19